Publications by authors named "Mark Saulnier"

Claim this Profile
P
Potent Long-Acting Inhibitors Targeting the HIV-1 Capsid Based on a Versatile Quinazolin-4-one Scaffold.
Eric P Gillis, Kyle Parcella, Michael Bowsher, James H Cook, Christiana Iwuagwu, Mark Saulnier

J Med Chem· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The discovery of BMS-737 as a potent, CYP17 lyase-selective inhibitor for the treatment of castration-resistant prostate cancer.
Chetan Padmakar Darne, Upender Velaparthi, Mark Saulnier, David Frennesson, Peiying Liu

Bioorg Med Chem Lett· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and Preclinical Profiling of GSK3839919, a Potent HIV-1 Allosteric Integrase Inhibitor.
Kyle Parcella, Tao Wang, Kyle Eastman, Zhongxing Zhang, Zhiwei Yin, Mark G Saulnier

ACS Med Chem Lett· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
5
5-Bromo-2-chloro-4-fluoro-3-iodopyridine as a Halogen-rich Intermediate for the Synthesis of Pentasubstituted Pyridines.
Yong-Jin Wu, Gerard J Porter, David B Frennesson, Mark G Saulnier

J Org Chem· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biochemical and transcriptional profiling to triage additional activities in a series of IGF-1R/IR inhibitors.
Petra Ross-Macdonald, Heshani de Silva, Vishal Patel, Amy Truong, Aiqing He, Mark Saulnier

Bioorg Med Chem· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insulin-like growth factor-1 receptor (IGF-1R) kinase inhibitors: SAR of a series of 3-[6-(4-substituted-piperazin-1-yl)-4-methyl-1H-benzimidazol-2-yl]-1H-pyridine-2-one.
Upender Velaparthi, Mark G Saulnier, Mark D Wittman, Peiying Liu, David B Frennesson

Bioorg Med Chem Lett· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors.
Kurt Zimmermann, Mark D Wittman, Mark G Saulnier, Upender Velaparthi, Xiaopeng Sang

Bioorg Med Chem Lett· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in clinical development.
Mark D Wittman, Joan M Carboni, Zheng Yang, Francis Y Lee, Melissa Antman, Mark Saulnier

J Med Chem· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nucleophilic capture of the imino-quinone methide type intermediates generated from 2-aminothiazol-5-yl carbinols.
Mark G Saulnier, Marco Dodier, David B Frennesson, David R Langley, Dolatrai M Vyas

Org Lett· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and evaluation of 4-(2-(4-chloro-1H-pyrazol-1-yl)ethylamino)-3-(6-(1-(3-fluoropropyl)piperidin-4-yl)-4-methyl-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one (BMS-695735), an orally efficacious inhibitor of insulin-like growth factor-1 receptor kinase with broad spectrum in vivo antitumor activity.
Upender Velaparthi, Mark Wittman, Peiying Liu, Joan M Carboni, Francis Y Lee, Mark Saulnier

J Med Chem· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Balancing oral exposure with Cyp3A4 inhibition in benzimidazole-based IGF-IR inhibitors.
Kurt Zimmermann, Mark D Wittman, Mark G Saulnier, Upender Velaparthi, David R Langley

Bioorg Med Chem Lett· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-(1H-Imidazol-4-yl)ethanamine and 2-(1H-pyrazol-1-yl)ethanamine side chain variants of the IGF-1R inhibitor BMS-536924.
Mark G Saulnier, David B Frennesson, Mark D Wittman, Kurt Zimmermann, Upender Velaparthi

Bioorg Med Chem Lett· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.
Paul Haluska, Joan M Carboni, David A Loegering, Francis Y Lee, Mark Wittman, Mark G Saulnier

Cancer Res· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity.
Mark Wittman, Joan Carboni, Ricardo Attar, Balu Balasubramanian, Praveen Balimane, Mark G Saulnier

J Med Chem· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor.
Joan M Carboni, Adrian V Lee, Darryl L Hadsell, Bruce R Rowley, Francis Y Lee, Mark Saulnier

Cancer Res· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a fluoroindolo[2,3-a]carbazole clinical candidate with broad spectrum antitumor activity in preclinical tumor models superior to the marketed oncology drug, CPT-11.
Mark G Saulnier, Balu N Balasubramanian, Byron H Long, David B Frennesson, Edward Ruediger

J Med Chem· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel 3',6'-anhydro and N12,N13-bridged glycosylated fluoroindolo[2,3-a]carbazoles as topoisomerase I inhibitors. Fluorine as a leaving group from sp3 carbon.
Mark G Saulnier, David R Langley, David B Frennesson, Byron H Long, Stella Huang

Org Lett· March 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and synthesis of a fluoroindolocarbazole series as selective topoisomerase I active agents. Discovery of water-soluble 3,9-difluoro-12,13-dihydro-13-[6-amino-beta-D-glucopyranosyl]-5H,13H-benzo[b]- thienyl[2,3-a]pyrrolo[3,4-c]carbazole- 5,7(6H)-dione (BMS-251873) with curative antitumor activity against prostate carcinoma xenograft tumor model.
Balu N Balasubramanian, Denis R St Laurent, Mark G Saulnier, Byron H Long, Carol Bachand

J Med Chem· March 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis